Lacripep for the Treatment of Primary Sjögren-Associated Ocular Surface Disease: Results of the First-In-Human Study.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Lacripep for the Treatment of Primary Sjögren-Associated Ocular Surface Disease: Results of the First-In-Human Study.
- Published In:
- Cornea, 42(7), 847-857 (2023)
- Database ID:
- RPEP-07454
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07454APA
Tauber, Joseph; Laurie, Gordon W; Parsons, Edward C; Odrich, Marc G. (2023). Lacripep for the Treatment of Primary Sjögren-Associated Ocular Surface Disease: Results of the First-In-Human Study.. Cornea, 42(7), 847-857. https://doi.org/10.1097/ICO.0000000000003091
MLA
Tauber, Joseph, et al. "Lacripep for the Treatment of Primary Sjögren-Associated Ocular Surface Disease: Results of the First-In-Human Study.." Cornea, 2023. https://doi.org/10.1097/ICO.0000000000003091
RethinkPeptides
RethinkPeptides Research Database. "Lacripep for the Treatment of Primary Sjögren-Associated Ocu..." RPEP-07454. Retrieved from https://rethinkpeptides.com/research/tauber-2023-lacripep-for-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.